ATC12 |
Catalog No.GC79044
One-Click Copy Product Info
|
ATC12 is a Aurora-A kinase inhibitor.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 384860-40-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vitro, ATC12 (1.56-100 μM; 10 min) disrupts the interaction between purified Aurora-AKDCM and the TPX21-43 peptide in vitro, with an IC50 of 25.6 μM[1]. ATC12 (10 μM; 24 h) reduces the formation of the Aurora-A/TPX2 complex on the mitotic spindle and the level of pT288 Aurora-A at spindle poles in U2OS osteosarcoma cells[1]. ATC12 (10 μM; 24 h) disrupts the formation of Aurora-A/TPX2 complexes in mitotic and interphase nuclei of MCF7 and MDA-MB-231 breast cancer cells, and reduces the nuclear level of Aurora-A[1]. ATC12 (30-50 μM; 0-48 h) inhibits the proliferation of MCF7 breast cancer cells, prolongs the mitotic process, reduces the cell growth rate, and induces apoptotic cell death[1]. ATC12 (30-50 μM; 0-72 h) inhibits the proliferation of MDA-MB-231 breast cancer cells, prolongs mitotic duration, reduces cell growth rate and induces cellular senescence without triggering cell death[1]. ATC12 (10-100 μM; 5 days) reduces the viability of patient-derived organoids BCO-21, BCO-46 and BCO-61 from triple-negative breast cancer (TNBC) in a dose-dependent manner[1].
References:
[1]. Boi D, et al. The ATC12 small molecule inhibits the Aurora-A/TPX2 interaction and impairs the proliferation of breast cancer cells. Cell Death Dis. 2026;17(1):356. Published 2026 Mar 24.
| Cas No. | 384860-40-6 | SDF | |
| Formula | C28H29NO3 | M.Wt | 427.53 |
| Solubility | Storage | Store at -20°C | |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.339 mL | 11.6951 mL | 23.3902 mL |
| 5 mM | 467.8 μL | 2.339 mL | 4.678 mL |
| 10 mM | 233.9 μL | 1.1695 mL | 2.339 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)